Doxycycline in Type II Diabetes

Mostafa Bahaa

Status and phase: Enrolling; Phase 2; Phase 1

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Doxycyclin; Drug: Sitagliptin 100mg

Study type: Interventional

Funder types: Other

Identifiers

NCT06329882

14789

Details and patient eligibility

About

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden

Enrollment: 60 estimated patients

Sex: All

Ages: 40 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female sex more than 40 years old Newly diagnosed type II diabetes. HbA1c more than 6.5

Exclusion criteria

• Patient with chronic kidney disease, hepatic disorders, mental and psychiatric disorders, pregnancy, and lactation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

control group

Active Comparator group

Description:

patients were on sitagliptin 100mg /day monotherapy

Treatment:

Drug: Sitagliptin 100mg

Comparative group

Active Comparator group

Description:

patients were on sitagliptin 100mg /day monotherapy plus doxycycline 100 mg

Treatment:

Drug: Sitagliptin 100mg

Drug: Doxycyclin